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Abstract
Background: Countries rely on out-of-pocket (OOP) spending to different degrees and employ varying techniques.
The article examines trends in OOP spending in ten high-income countries since 2000, and analyzes their
relationship to self-assessed barriers to accessing health care services. The countries are Australia, Canada, France,
Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States.
Methods: Data from three sources are employed: OECD statistics, the Commonwealth Fund survey of individuals in
each of ten countries, and country-specific documents on health care policies. Based on trends in OOP spending,
we divide the ten countries into three groups and analyze both trends and access barriers accordingly. As part of
this effort, we propose a conceptual model for understanding the key components of OOP spending.
Results: There is a great deal of variation in aggregate OOP spending per capita spending but there has been
convergence over time, with the lowest-spending countries continuing to show growth and the highest spending
countries showing stability. Both the level of aggregate OOP spending and changes in spending affect perceived
access barriers, although there is not a perfect correspondence between the two.
Conclusions: There is a need for better understanding the root causes of OOP spending. This will require data collection
that is broken down into OOP resulting from cost sharing and OOP resulting from direct payments (due to
underinsurance and lacking benefits). Moreover, data should be disaggregated by consumer groups (e.g. income-level or
health status). Only then can we better link the data to specific policies and suggest effective solutions to policy makers.
Keywords: Access, Coinsurance, Copayments, Deductibles, Cost-sharing, Comparative health systems, Out-of-pocket costs
Background
All countries rely on out-of-pocket (OOP) spending to help
fund their health care systems. OOP spending includes
both direct payments made for uncovered services (due to
lack of insurance or lacking benefits) and cost sharing
requirements such as coinsurance and deductibles. It serves
two main purposes: as a source of revenue, and to help
reduce demand for services. However, controversy sur-
rounds OOP payments and opponents typically voice two
concerns. Charging people for their medical care means
that those with the greatest need, and those with the lowest
income, will feel the brunt. Moreover, patients may forgo
necessary care - in contrast to other forms of financing
such as taxes and premiums, which cannot be avoided by
forgoing health care.
In recent years there is a perception that in many coun-
tries costs are being shifted to patients. Policy interest,
therefore, is high, but there has been little cross-country
research on actual trends in OOP spending or on consumer
perceptions of reductions in access that result from higher
OOPs. The purpose of this article is to: (a) systematically
assess trends in OOP spending in ten prominent high-
income countries as well as trends in people’s perception of
any resulting impediments regarding accessing needed
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medical care; and (b) discuss some of the policies respon-
sible for these trends. As part of this effort, we propose a
conceptual model for understanding the key components
of OOP spending.
The four most relevant previous studies published
since 2010 are presented in Table 1 [1–4]. The one most
similar to the current study [4], by Zare and Anderson,
examines four of the ten countries in the current study,
although in the U.S. it examines only the Medicare pro-
gram and has a somewhat shorter time period (2000–
2010). Our study differs from previous ones in several
important ways that extends our understanding of OOP
payments trends across countries. Most previous re-
search considers OOP spending only in terms of cost
sharing policies. This overlooks the important role of
direct payments for uncovered services, which in some
countries may play a larger role in OOP spending, as
does the complicated interplay with Voluntary Health
Insurance. Such insurance strongly affects levels of OOP
spending. In addition, this study examines recent
changes in OOP policy in each country. Moreover, un-
like previous research, we examine the financial barriers
of OOP spending with regard to reducing access to care.
Overall, the study attempts to link three things: aggre-
gate trends in spending, perceived barriers to access, and
governmental health policies.
Methods
Choice of countries and time period
Our choice of countries was based on the data available
for self-reported access barriers due to OOP spending.
To assess these barriers, we use a long time-series of
household survey data collected by the Commonwealth
Fund. This survey now includes data from 11 countries:
Australia, Canada, France, Germany, the Netherlands,
New Zealand, Norway, Sweden, Switzerland, the U.K.,
and the U.S. For the quantitative analysis of trends in
spending and perceived access barriers, we include all 11
countries. When describing policy changes since 2000,
however, we exclude New Zealand because of the diffi-
culty of obtaining accurate historical policy data. The
European Observatory for Health Systems and Policies
regularly publishes updated books on developments in
health policy in its Health Systems in Transition series.
While the other countries’ books have all been updated
since 2011, New Zealand’s book dates back to 2001 [5].
Table 1 Recent Previous Research on Out-of-Pocket Spending
Study Countries Data/Variable Key Findings Relevance
Baird, 2016 [1] Australia, France, Israel,
Japan, Poland, Russia,
Slovenia, Switzerland,
United States
Individual survey on OOP
spending compared to income
from Luxembourg Income Study
(2010 for most countries)
• In median country, 13% of
people spend more than 10%
of income in OOP.
• Varies from 3% (France) to
17% (Switzerland).
• Poor and elderly at greatest
risk of cata-strophic spending.
• Focuses on percentage
of population with high
OOP spending during
a single year.
• Emphasizes groups
that are most financially
vulnerable.
• Does not examine
countries’ health policies.
• Does not examine
perceived barriers on
access to care.
Palladino et al.,
2016 [2]
Austria, Belgium, Czech
Republic, Denmark, France,
Germany, Netherlands,
Spain, Sweden, Switzerland
Survey of people age 50 and
older from Health, Ageing and
Retirement in Europe, with
data on changes in OOP
spending and experiencing
catastrophic OOP spending
(30% or more of income),
from 2006/7 to 2013
(Great Recession)
• Very large range in changes
in OOP spending (− 11% in
Netherlands to + 101% in Austria).
• Increase in catastrophic spending:
from 2.3 to 3.9% over study period.
• People age 50 and older spent
more in 8 of11 countries.
• Countries do provide financial
protection for poor.
• Focuses on changes in
OOP spending during
limited time period.
• Does not examine
countries’ health policies.
• Does not examine
perceived barriers
on access to care.
Tambor et al.,
2011 [3]
27 countries in the
European Union
Review of international
data bases, laws and
regulations, and reports
on changes in patient
cost sharing requirements
since 1990
• Cost-sharing requirements vary a
great deal between countries, and
have increased significantly in many.
• Tax-based systems more likely to
use co-payments, insurance-based
systems more likely to use deductibles
and coinsurance.
• Almost all countries have policies
to protect the poorest and/or sickest.
• Focuses on health
policies in countries,
but little detail provided.
• Includes extremely
diverse set of countries.
• Does not examine
perceived barriers
on access to care.
Zare & Anderson,
2013 [4]
France, Germany, Japan,
United Kingdom, United
States (Medicare only)
Various data sets from OECD, WHO,
European Observatory, and country-
specific reports, time period 2000–2010;
separately examine cost sharing for
pharmaceuticals, inpatient, and
ambulatory care
• Inflation-adjusted OOP spending, and
spending divided by income, increased
in all countries.
• Percent of total national health care
paid OOP declined in most countries
due to protection mechanisms for
poor and/or sick.
• Focuses on health
policies in 5 countries.
• Does not examine
perceived barriers
on access to care.
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The study time frame varies for different parts of our
study. When examining aggregate data from the OECD
and Commonwealth Fund, we consider the date range
from 2000 to the most recent time period. When exam-
ining details about how OOP costs have changed in the
individual countries, data back to 2000 was not always
available. Therefore, we focused on an approximately
10-year period, beginning in 2005 for most countries.
Conceptualizing out-of-pocket costs
Definition of terms
This study conceptualizes OOP spending as the sum of
cost sharing requirements for covered or insured ser-
vices, direct payments for uncovered/uninsured services,
and informal payments. It does not include premium
payments. Because informal payments are negligible in
our set of countries, we do not consider them further.
There are three issues, however, that complicate imple-
menting this definition.
The first concerns the use of aggregate annual OOP
spending vs. spending for an individual service. Later in
the article, we show that in many of the ten countries
examined here, inflation-adjusted, aggregate OOP spend-
ing has not risen very much over the past decade. This is
sometimes assumed to mean that OOP expenses are not
a growing problem. This is not correct, however. If cost
sharing requirements increase, people may respond by
using fewer services, which obscures the true impact of
growing cost sharing requirements because lower usage
will result in lower aggregate OOP payments. The more
appropriate way to examine whether people are facing
an increase in the financial barriers that result from
OOP payments is to examine how coverage and benefit
policies as well as cost sharing requirements are chan-
ging over time, not how much aggregate OOP payments
are changing. This is discussed in more detail below and
presented graphically in Fig. 1.
A second issue relates to disentangling the role of vol-
untary health insurance (VHI). These products serve a
variety of purposes, depending upon country. The most
basic and common forms include supplementary VHI,
which pays for services that are not covered by the na-
tional health plan (e.g., dental care), and complementary
VHI, which pays for cost-sharing requirements for
services covered in the national plan (if allowed under
national legislation, as it is often seen as undermining
the utilization-reduction effect). In some countries, VHI
may also serve as a primary (“substitutive”) insurance
coverage scheme. Finally, VHI sometimes can help pa-
tients get access to care without waiting as long as
others who are obtaining public care but who lack VHI.
If services are paid for by VHI, they do not constitute
OOP spending. But lower OOP spending does not
necessarily mean lower financial barriers, as it may be
more costly in premiums to purchase VHI than to
simply pay the OOP.
Finally, we do not examine OOP spending for long-
term care (LTC), for two reasons. First, the countries
examined have very different LTC schemes with widely
diverging rules regarding patient responsibility for LTC
costs, such that it was not possible to summarize these
requirements without a large number of caveats. Second,
LTC costs, to a large extent, fall only on one segment of
the population – the elderly.
Analytic framework
With these issues in mind, we propose an analytical
framework that is based on the three-dimensional cube
that was first proposed by Busse et al. 2007 [6, 7] and
which was subsequently adopted by the WHO in their
World Health Report 2010 [8]. The 2007 framework
captures the three dimensions of population coverage
(breadth), scope of services (depth) and level of coverage
(cost-sharing). Our revision has added the level of OOP
and VHI to these dimensions (see Fig. 1). This allows us
to systematically analyze the specific sources and com-
ponents of OOP payments as well as the role of VHI.
The three dimensions, along with related policies, to-
gether determine the level of OOP. The first dimension
is about who is covered (breadth). OOP payments may
arise as a result of direct payments due to lack of insur-
ance. The second dimension concerns which services
are covered (scope). In this case OOP payments occur as
direct payments resulting from lacking benefits/under-
insurance. The third dimension relates to what propor-
tion of benefit cost is covered (depth). Here, OOP
payments may occur if cost-sharing schemes apply that
require insured/covered individuals to pay a share of the
benefit cost. As an important subcategory of OOP pay-
ments, cost sharing may take several forms. The most
well-known are direct methods (copayment, coinsur-
ance, and deductibles) and indirect methods (e.g. extra
billing, reference pricing).
In the presentation of the study results regarding
“Country-Specific OOP Policies,” below, we employ
these concepts of breadth, scope, and depth in present-
ing current policy and trends. Ideally, to fully understand
these policies and trends, one would conduct separate
analysis of how three determinants of OOP spending
have changed over time in each of the ten countries, but
that is beyond the scope of this article and likely would
fill a lengthy monograph.
Objective trends and perceived access barriers
One of the purposes of this study is to determine if there
is a relationship between objective, aggregate OOP
spending and perceptions of barriers to access. While
there is certainly face validity to the hypothesis - if
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people have to spend more per service, economic the-
ory would tell us they will use less - there are reasons
for suspecting that this sort of causal relationship
may be mitigated.
In the typical international definition, which we em-
ploy here, premiums are not counted towards OOP
spending. [9] But premiums, of course, can reduce the
use of needed services. In countries without universal
coverage, like the U.S., premiums form a major barrier
towards obtaining coverage [10]. Moreover, through an
income effect, high premiums reduce disposable income,
making less income available for purchasing health care
services. A similar scenario relates to taxes. Payroll
deductions for health care coverage, which are common
in many social insurance countries, also reduce dispos-
able income. Finally, these same issues apply to VHI:
depending on how visible VHI premium payments are to
the individual, they may also be viewed as a barrier to
accessing care.
Moving away from definitional concerns, perceived
access burden is likely to be affected by distributional
issues that are difficult to observe in aggregate data.
Countries that have a relatively low maximum on indi-
vidual OOP expenditures are likely to see these costs
spread out more equally among the population, meaning
that fewer people will perceive cost-related access prob-
lems. In contrast, if there are high or even non-existent
maximum spending thresholds, then some (sicker)
people will be subject to higher spending and are more
likely to experience access burdens. More broadly, a
country’s social safety net is an overarching determinant
of perceived access burdens.
Data sources and analysis
OECD data on OOP spending, from the years 2000 to
the most recent available, are used to show aggregate
trends in such spending by country. In addition, longitu-
dinal, country-specific consumer survey data from the
Commonwealth Fund are used as the source of per-
ceived financial access problems. Sample sizes ranged
from 1000 to over 7000, depending on country.
However, much of the study data come from individual
country sources (e.g. legislation, national reports). Specif-
ically, we sought information on current levels and
changes in both cost sharing requirements and direct pay-
ments for uncovered services. One primary source were
the book series, Health Systems in Transition, published
by the European Observatory on Health Systems and
Policies. [11] Country-specific sources are also used when
discussing the policy modifications that were responsible
for changes in OOP spending.
Linear regressions were used to test whether trends in
OOP spending differed across countries categorized to
have historically low OOP costs with higher recent
growth, historically moderate OOP costs with lower re-
cent growth, or historically high OOP costs with low to
no growth in recent years. In the analyses, the probabil-
ity of making a type I error was set to 0.05.
Results
Aggregate trends in OOP spending by country
Comparing OOP spending data over time and between
countries is very difficult due to frequent breaks in the
data, as well as differing definitions and variations in
reporting between countries. We aim to compensate in
Fig. 1 Three dimensions determine the level of out-of-pocket spending. Adapted from Busse and Schlette, 2007 [7]
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part for these limitations by focusing on longer, succes-
sive, ten-year intervals rather than year-on-year in-
creases, the latter often showing skewed results due to
changes in data collection methodology. Figure 2 plots
OOP spending per capita in 2004 and 2014 (in PPP and
constant prices) versus growth rate averages in two previ-
ous 10 year intervals (i.e. time periods 1994–2004 and
2004–2014). The beginning of each line, represented by “x,”
shows the average annual rate of increase in PPP-adjusted
per capita in OOP spending during the 1994–2004 period.
The end of each line, represented by the arrowhead, pro-
vides the same rate for the 2004–2014 period.
The figure suggests that there are three logical groupings
of countries. First, countries where historically OOP spend-
ing has been lower compared to the others (UK,
Netherlands, France) and which have experienced higher
recent growth rates (2004–2014 compared to 1994–2004).
The second group consists of countries in which OOP
spending is in the middle range (Sweden, Australia,
Germany, Canada); they have experienced a decreasing rate
of growth when comparing the period 1994–2004 with
2004–2014, but OOP payments are still increasing. Finally,
the third group consists of countries that have consistently
experienced the highest OOP spending (Norway, United
States, Switzerland), with some growth in 1994–2004, but
little change in spending between 2004 and 2014. Thus, the
more countries spent on OOP payments, the lower the
growth rate. It is important to be aware that the reported
figures are in constant US$ purchasing power parities (PPP).
This is useful if one wants to compare OOP spending
patterns over time and across countries. However, the fact
that in some countries there was little to no increase in
Fig. 2 OOP spending per capita (in PPP and constant prices) vs growth in OOP per capita (in PPP and constant prices), from 1994-2004 vs. 2004-2014.
Note: The base of each line, represented by “x,” shows the average annual rate of increase in PPP-adjusted per capita in OOP spending during the 1994-2004
period. The end of each line, represented by the arrowhead, provides the same figure for the 2004-2014 period. Countries are combined into three groups.
The blues lines represent countries with historically low OOP spending; the red, countries with historically high OOP spending; and the yellow, countries with
mid-level historical OOP spending. Source: adapted from OECD Health Statistics, 2017 [12]
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constant US$PPP does not mean that there was no increase
in spending when expressed in the local currency or that no
extra cost-sharing requirements were implemented. For
example, although Norwegian OOP spending growth in the
period 2004–2014 seems minimal in Fig. 2, OOPs per capita
increased from approximately 5740 to about 8215 when
expressed in Norwegian Krone (NOK) [12].
To confirm that the three groups did indeed experi-
ence divergent trends depicted in Fig. 2, a linear regres-
sion model was used. The results of this test, shown in
Table 2, indicate that the three groups of countries
indeed differed in their growth rate in OOP costs per
capita in the decade prior to 2004 compared to the dec-
ade that followed. Specifically, those with historically low
OOP costs but higher recent growth experienced an
average increase of 3.63% (group 1), while those with
historically moderate OOP costs with lower recent
growth declined (group 2, − 3.00%, p < 0.001), as did
those with historically high OOP costs with low to no
recent growth (group 3, − 3.56%, p < 0.001). There were
no significant differences in growth rates between these
latter two country groups.
These trends illustrate our first key finding: a gradual
convergence in OOP spending between countries. The con-
vergence, of course, is slow in coming, since from a low
base even a large increase in the percentage growth consti-
tutes a relatively small increase in dollar or euro spending,
when compared to low growth from a high base.
Country-specific OOP policies
In this section, we analyze changes in the barriers imposed
by OOP payments by examining how policy modifications
affect the breadth, scope, and depth of coverage over the last
decade. For an overview of current policies in each country
except New Zealand, refer to the Table 1 in Appendix, and
for changes in such policies over the past decade, Table 2 in
Appendix. Here we will focus on the changes between 2004
and latest available year. We discuss the countries according
to the three groups as identified in Fig. 2.
Group 1: Historically low OOP costs, higher recent growth
(France, Netherlands, UK)
OOP spending in France is the lowest among the ten
countries and has remained fairly stable in spite of some
recent increases. For decades, France has had broad uni-
versal coverage of the population through statutory
health insurance and near universal complementary
coverage. This means that OOP does not occur as a
result of lacking breadth or scope, but rather from cost-
sharing requirements (depth). Nominal co-payments are
charged for almost all physician services, hospital
services, auxiliary services, prescription drugs, vision
care, and dental care. Each type of health service has an
annual cap of around €54, but these are additive. Gener-
ous exemptions from cost sharing payments as well as
free complementary VHI (also through vouchers) exist
for the poor, those with chronic illness, and women
more than five months pregnant. Starting in 2010 all
those with an annual income below €11,611 (reduced to
€9825 in 2016) received vouchers to purchase comple-
mentary VHI. There is some extra billing for full-time
public hospital doctors and a few other professional
medical groups. In 2016 a major change in OOP charges
was implemented: a daily hospital co-payment of about
€18 for medical or surgical procedures that cost in
excess €120. Many patients, however, are exempt from
these out-of-pocket charges. Overall, growth in OOP
seems to relate to small increases in cost sharing
requirements in the form of co-payments.
Like France, the Netherlands historically has had very
low per capita OOP spending. OOP spending in the
Netherlands mostly is the result of direct payments due
to changes in the benefit basket and various cost sharing
requirements. Unfortunately, OOP spending data cannot
be separated into cost sharing vs. direct payments due to
the health care accounting practices in the Netherlands.
Although there have been yearly changes in the benefit bas-
ket by adding or removing services and pharmaceuticals, it
is nevertheless likely that increases in cost sharing require-
ments are responsible for changes in OOP spending, mostly
as a result of rising deductibles. Starting in 2008 a €150
deductible was established (exempting GP care, maternity
care, and care for children under 18), and it has increased
more than 2.5 fold, to €385, in 2016. Moreover, the delisting
of certain services (e.g. dental care for adults) may have had
some effect on increasing direct payments, although the
impact was mitigated by the high rates of participation in
voluntary health insurance. Direct payments are required
for some drugs, adult dental care, and some medical equip-
ment, among other things. Indeed, in 2015, 84.1% of all in-
sured purchased VHI, which typically covers dental care
(73% of Dutch people) and physiotherapy [13].
Historically, the U.K. has not systematically excluded
benefits (it rather provides services “to such extent as
Table 2 Differences in Growth in Out of Pocket Costs Between
Country Groupings
Predicted Mean Percent
Change in OOP/Capita
1994–2004 vs. 2004–2014
p-value
Group 1 - Historically low
OOP costs with higher
recent growth
3.63 reference
group
Group 2 - Historically moderate
OOP costs with lower
recent growth
−3.00 < 0.001
Group 3 - Historically high
OOP costs with low to no
recent growth
−3.56 < 0.001
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[considered] necessary to meet all reasonable requirements”
[14]. This means that the relatively high growth in OOP
(2nd after the Netherlands) in 2004–2014 must be mostly
ascribed to increased cost sharing requirements. Still, per
capita OOP spending has been very low by international
standards, with only those in France spending less. In-
patient and outpatient services are received free at point of
service in most cases, but there are co-payments for pre-
scription drugs that have been growing and amounted to
£8.40 per prescription in 2016. These co-payments were
capped at £104 annually in 2009 and remain the same
today. Furthermore, although the co-payment maximum
was lowered in 2006 (from £384 to £189), there have been
regular increases since then. Similarly, there are co-
payments for dental services (the amount of which varies
by service). Both drug and dental co-payments have risen
by 2% per year since 2005. Children and students, those
age 60 and above, people with specific medical conditions
and those on low-income schemes are exempted from co-
payments for drugs and dental services, and are covered for
vision services (which is normally not covered). Unsurpris-
ingly, the market for VHI is rather small. Individuals buy
VHI to avoid waiting lists, have some choice over the phys-
ician they visit, and for more comfortable rooms [15].
Group 2: Historically moderate OOP costs, lower recent
growth (Australia, Canada, Germany, Sweden)
The Australian Medicare system provides universal popula-
tion coverage. OOP occurs mostly due to a lack of scope of
benefits, particularly dental benefits, and various cost shar-
ing requirements. Indeed, although the system fully covers
care in public hospitals, it requires co-payments for most
other services as well as care in private hospitals. Per-
service co-payments for GPs have grown considerably in
recent years, rising from $AUD 11.8 (€8.02) in 2005 [16] to
$AUD 29.56 (€20.10) in 2014 [17], a 2.5-fold increase, with
most of the increase occurring since 2009. Other services
that have experienced significant aggregate increases in
OOP expenditures over recent years are prescription drugs,
specialist care, and dental care. The timing of these changes
appears to relate to a change in national government dating
from 2013. The new government has been attempting to
reduce national health outlays. Australia is unusual in that
the government provides strong incentives for people to
purchase private supplementary VHI, and close to half of
the population does so. VHI typically covers the higher user
charges of private hospitals, and helps reduce co-payments
for other services. Significantly, however, it does not cover
co-payments for GP services. Interestingly, a recent survey
shows an emerging disillusionment with private insurers, as
membership is declining and 75% of young adults consid-
ered downgrading or dropping their policy in the past
12 months [18].
The Canadian health system, governed by the Canada
Health Act of 1984, provides universal population coverage.
The benefit package includes inpatient and most outpatient
care but excludes some important categories including out-
patient prescription drugs, dental, or vision care. This re-
sults in substantial OOP due to direct payments, mostly for
pharmaceuticals. It is difficult to generalize much beyond
this because each of the 13 provinces and territories
chooses the extent to which it covers such services. For
example, each has its own pharmacy benefits program and
formulary and the prevalence of complementary VHI
coverage also varies. Complementary insurance covers
many of the potential OOP costs and some provinces re-
quire employers to provide it for employees. Furthermore,
beginning in 2010 most provinces adopted catastrophic
income-based pharmacy insurance that protects individuals
for catastrophic costs in purchasing medications. In almost
all cases the OOP costs for the very poor are covered
through a variety of federal and provincial programs. Since
the number of changes has been limited, OOP has grown
moderately in the period 2004–2014. Some provincial inno-
vations stand out. Ontario is implementing publicly funded
universal comprehensive drug coverage, called “pharma-
care,” for children and youth.
The German system provides universal population cover-
age either through social health insurance (SHI) (almost
90% of the population) or substitutive VHI. As OOP
policies of substitutive VHI vary widely (and data is largely
unavailable), we focus on SHI. OOP spending in Germany
is related to both direct payments for services not covered
by SHI (e.g., over-the-counter drugs) and cost-sharing for
SHI covered services, but the relative importance of cost-
sharing versus direct payments is not known because of the
health system’s accounting methods. OOP spending above
reference prices for dental care and medical aids can be
substantial; for example, reference prices for dental care
cover only about 50% of the costs of standard care. Cost-
sharing requirements increased in 2004 for such things as
prescription drugs, inpatient care, and physician and dental
care, while at the same time adult eyeglasses were excluded
from coverage. Since these increased requirements became
effective in 2004 they do not affect the average growth rate
in the 2004–2014 period and therefore do not contradict
the observed drop in average growth in 2004–2014 com-
pared to the 1994–2004 period. The most plausible explan-
ation for the low growth in this period is the fact that in
2013, co-payments for physician visits were discontinued.
The most important protection mechanism against OOPs
is the exemption of children under 18 years of age and a
maximum cost-sharing limit of 2% of annual income (or
1% for patients with severe chronic conditions). This has
remained largely unchanged over the study period.
Sweden’s health system provides universal population
coverage for a broad basket of services. The majority of
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OOP is thus attributable to cost sharing requirements.
These include co-payments for most health services adults
use in Sweden, including hospitalization. Co-payments for
health care visits and hospitalization vary across the 21
counties although policies have converged over time. Co-
payments are differentiated to steer patients towards use
of primary care during office hours. Co-payments for
visits to specialist doctors without a referral are about
twice as much as for a regular visit to a primary care doc-
tor. In most counties children below age 20 are exempt
from co-payments. There is a combined cap for each
12 month period determined at the national level, maxi-
mizing total co-payments for outpatient care. Deductibles,
co-payments and caps for prescription drugs and dental
care are determined fully at the national level. Dental care
for individuals under age 22 is free. For adults, there is a
deductible of SEK 1000 (€103) for prescription drugs
followed by a stepwise increase in subsidies ending in a
12 months cap of SEK 2200 (€226). For dental care to
adults, the deductible is SEK 3000 (€308), followed by in-
crease in co-insurance to 85% above SEK 15,000 but with-
out an overall cap. Additional minor changes in terms of
additional subsidies for dental care to elderly were intro-
duced in 2013. In 2009, prescription cost-sharing policy
was changed such that patients now usually pay the full
price for generic alternatives that are not the lowest cost
generic. In 2012 cost-sharing limits on prescriptions as
well as for outpatient services were increased (from SEK
1800 to SEK 2200 (€ 185–226) and SEK 900 to SEK 1100
(€ 92–113) respectively). These increased cost sharing re-
quirements seem not to have had great impact on the
average growth rate in 2004–2014, which was lower than
in the previous period. This can perhaps be explained by
the fact that the requirements were relatively minor and
partially offset by better dental benefits.
Group 3: Historically high OOP cost, low to no growth in
recent years (Norway, Switzerland, United States)
Norwegians enjoy universal population coverage for a broad
basket of benefits. OOP payments relate to cost sharing for
most health care services with the exception of inpatient
care. The majority of acute-care OOP payments are associ-
ated with outpatient care, dental care, and prescription drug
use. Cost sharing requirements have not changed much in
the past decade and OOP spending has remained at a stable
yet high level. Requirements are set nationally for designated
services and populations. For example, general practitioner
and outpatient specialist co-payments were NOK 152/201
(€16/21) (depending on level of education of GP) and NOK
345 (€37) in 2017. Prescription drugs deemed essential and
on an approved list called the “blue list” can cost as much as
NOK 520 (€55) per prescription. Two different cost-sharing
ceilings are set by Parliament annually. The first ceiling was
NOK 2205 (€234) in 2017 and is a limit on cost-sharing
amounts paid to physicians, psychologists, hospital care, radi-
ology and blue-list drugs. The second ceiling was NOK 1990
(€211) in 2017 and limits OOP spending on physiotherapists,
eligible dental care (identified conditions), some rehabilita-
tion services, and treatment abroad (if referred by Oslo
University hospital). Certain diseases (e.g. many communic-
able disease) and patients (e.g. children, the disabled, preg-
nant women) are subject to reduced or no cost-sharing while
services like adult dental care face the highest cost-sharing.
The Swiss system provides universal population coverage
for a broad basket of services. There have been some
changes to cost-sharing requirements in Switzerland since
the early 2000’s. In 2004, the minimum deductible increased
from CHF230 (€210) to CHF300 (€275) and the maximum
deductible increased in 2005 from CHF1500 (€1373) to
CHF2500 (€2288). In 2006, coinsurance increased to 20%
for brand drugs if a cheaper generic is available. Direct pay-
ments were affected by the exclusion of eye glasses from
coverage in 2011, and the inclusion of complementary and
alternative medicine into the benefits package in 2012. In
fact, direct payments account for about 80% of all OOPs.
Given the diversity of insurance plans in Switzerland the re-
liance on OOPs is also affected by changes in choices made
by those purchasing coverage. The share of the population
opting for insurance plans with higher deductibles (in ex-
change for lower premiums) has increased considerably over
time. For example, the proportion with a deductible of more
than CHF2000 (€1830), increased from less than 15% in
2009 to almost 23% in 2014. Over the same period of time,
the proportion of the population opting for insurance plans
with limited choice of providers increased from about 35%
to about 62% as a result of similar attempts to exert down-
ward pressures on premiums through benefit design.
The United States is the only country of the ten that has
substantial OOP costs due to direct payments resulting
from uninsurance. However, these costs have almost
certainly gone down during the Obama administration be-
cause many people obtained coverage under the Affordable
Care Act (ACA), which expanded the scope of the Medic-
aid program for the poor in many states and mandated
people not covered elsewhere to insure themselves through
insurance exchanges. As a result uninsurance among the
adult population age 18 and older dropped from 17.1% in
2013 to 11.0% in 2016 [19]. (The rate is closer to 9% when
the entire population is included since children’s uninsur-
ance rates are lower.) Still, many Americans lack insurance
coverage and pay for all costs out of pocket.
Unlike other high-income countries, Americans receive
insurance benefits through a number of sources: employers,
Medicare (seniors and the disabled), Medicaid (low-income
persons and some disabled), and through individual cover-
age, some of which is purchased from private insurers in the
ACA’s insurance exchanges. OOP payments are best consid-
ered within each of the main coverage types.
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 Medicaid covers a very wide scope of services and
this coverage is deep, with minimal cost sharing
requirements. As noted, the breadth of program
coverage has risen dramatically in recent years,
particularly due to expansion under the ACA,
doubling from 35 million people in 2000 to 70
million in 2016. One of the main problems is that
physician payment rates are so low in some states
that it is difficult for program enrolees to find
primary care and specialist physicians to treat them.
 The breadth of Medicare coverage is nearly
universal in the age 65+ population; the program
covers many disabled people as well. Since 2006,
with the implementation of prescription drug
benefits, nearly all types of services are covered.
Depth of coverage is relatively low with coinsurance
rates as high as 20% for physician services and no
out-of-pocket ceiling. As a result, 86% of Medicare
beneficiaries have supplemental coverage [20] to pay
for many coverage gaps. Sources include subsidized
coverage from former employers, unsubsidized
“Medigap” private insurance coverage (which is
mainly complementary), and Medicaid for those
with low incomes. Cost sharing requirements
change only modestly year to year.
 Just over half of insured Americans receive coverage
through employers. The scope of services covered
tends to be broad. However, cost sharing requirements
in such plans have risen steeply in recent years. The
most dramatic changes have been for deductibles. On
average, annual deductibles for employees who are only
covering themselves have gone up almost 2.5-fold,
from $602 in 2005 to $1478 in 2016. There have also
been substantial increases in the maximum OOP costs
beneficiaries can incur each year. In 2005, 33% of
employees had a maximum of $3000 or more. But in
2016, this had risen to 66%. Depending on the insurer
and type of service, employees are also subject to
coinsurance or co-payments, but these requirements
have been relatively stable over time except for brand-
name drugs that are not on an insurer’s formulary.
Most employees do not have coverage for dental care
and vision services; for those that do, cost sharing
requirements changed little over the past 10 years.
There is no major market for complementary coverage.
The main supplementary coverage is for dental care.
 Beginning in 2014, individuals have also obtained
coverage on the ACA’s insurance exchanges.
Deductibles are quite high in the most commonly
purchased “Silver” plans, averaging almost $3600 in
2017 [21].
U.S. cost-sharing has been rising mostly in the
employment-based markets. The reasons for rising
deductibles are straightforward: they provide a way of mod-
erating premium increases – which have risen much more
slowly than deductibles. In view of these deductible in-
creases, the most likely explanation for relatively stable ag-
gregate OOPs shown in Fig. 2 is that OOP growth resulting
mainly from deductible increases has been compensated (in
the aggregate) by lower utilization. A second reason is that
the expansion of Medicaid under the ACA has offset some
the aggregate effects of the employer and individual market
deductible increases since Medicaid has few cost-sharing
requirements. Finally, most people who originally obtained
coverage on the ACA exchanges were previously uninsured
[22], so the ACA resulted in a net reduction in these
people’s OOP spending.
Perceived access problems and the role of OOP spending
Many factors determine whether people will report that
they experienced a cost-related access problem. We
focus on its relationship to levels and changes in OOP
spending but other factors - not examined in this study -
can be important as well. Earlier we mentioned expenses
that are not included in the definition of OOP spending,
such as insurance premiums and taxes, may affect re-
sponses to questions about perceived reduction in access
to care. But beyond the definitional, individual character-
istics such as current socioeconomic status, changes in
that status, income distribution, employment, and
country-specific differences in attitudes about access to
care may also affect responses.
The Commonwealth Fund survey asks respondents
about three aspects of perceived access, and compiles
country-specific statistics on the percentage of adults
who: (1) did not see a doctor when sick, (2) skipped
a medical test or treatment recommended by a doc-
tor, or (3) did not fill a prescription or skipped a dose
because of cost in the past year. The data in Fig. 3
show the percentage of adult respondents who experi-
enced any of these three things. Countries are
grouped as they were in Fig. 2 (solid lines are the
highest spending countries), dotted lines the lowest
spending, and dashed lines the middle spending coun-
tries. In 2016, the U.S. had by far the highest rates of
reported access problems, and the U.K. the lowest,
with Germany, Netherlands and Sweden also low. We
are particularly interested in country-specific trends
over the study period to see if they correlate with
changes in a country’s policies regarding what services
are covered and, for covered services, cost sharing
requirements. Thus, perceived OOP barriers within
countries in each of the historical spending categories
are described below to contextualize self-reported
access problems in terms of national OOP spending
trends.
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Group 1: Historically low OOP costs, higher recent growth
(France, Netherlands, UK)
The most noteworthy pattern in Fig. 3 is the dramatic
fluctuation in perceived barriers to access in the
Netherlands. Only 6% of Dutch reported one of the ac-
cess problems in 2010, but this almost quadrupled to
22% just three years later. Interesting, the burden fell
back to historical levels (8%) by 2016. The surge between
2010 and 2013 is likely the result of the institution of de-
ductibles and then their fast increase in deductibles. The
highest year-to-year increase in deductibles took place
between 2011 and 2013, when the deductible increased
from €170 to €220 (2012) and to €350 (2013). When de-
ductible growth had levelled off by 2016, the reported
access barriers also reduced.
Perceived barriers were very low and reasonably steady in
the U.K., consistent with residents’ low OOP spending re-
sponsibilities and lack of major changes in policy. It rose
somewhat in France, but what is more surprising is that a
country with such low OOP spending shows the third high-
est rate of perceived barriers in 2016. While the reasons for
this are not clear, one possibility is that most OOP spending
in France is for primary care services, which most people
use. As noted, there are small co-payments required for
physician, hospital, and auxiliary services, prescription
drugs, and vision and dental care. The small increases in re-
ported access problems in France between 2010 and 2016
likely relate to higher co-payments (i.e., the co-payment for
hospital care in 2013). These trends may have led to re-
forms adopted in 2016 that will help poorer persons obtain
complementary insurance policies. Starting in 2016 health
insurance including complementary coverage was guaran-
teed to the poor in France free of charge. Those with low
income will no longer have to prove employment to qualify
for complementary VHI – three months of stable and regu-
lar professional activity or mere residence is sufficient [23].
Group 2: Historically moderate OOP costs, lower recent
growth (Australia, Canada, Germany, Sweden)
In line with country-level trends in OOP costs growth
slowing, two countries in Group 2 had substantial
decreases in self-reported access problems: Germany
(between 2010 and 2016) and Australia (over the entire
time period). The former may be the result of the discon-
tinuation of co-payments for physician services in 2013. It
is difficult, however, to explain the decline in perceived
access problems in Australia. Since 2004 the reporting of
access problems has fallen in spite of substantial increases
in co-payments for GP, specialist, and dental services and
pharmaceuticals. Perhaps the existence of VHI plays a role
in protecting individuals from high OOP. However, enrol-
ment rates have been relatively steady, at just under half
of the population, since 2000.
Canada and Sweden have reported relatively few - and
stable - cost-related access problems. This is in line with
Fig. 3 Percent adults reporting any of three access problems due to costs. Source: Commonwealth Fund, 2016 [29]
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our observation that benefit baskets and cost sharing
requirements in these countries have been fairly stable.
Group 3: Historically high OOP cost, low to no growth in
recent years (Norway, Switzerland, United States)
The country with the highest reported access problem is the
U.S. This is not surprising given both high uninsurance rates
and high levels of cost-sharing, particularly in employer-
sponsored coverage. Nevertheless, reported access barriers
declined considerably between 2004 and 2016. In the earlier
period, a contributing factor for the decline was almost cer-
tainly the 20% rise in Medicaid enrolment between 2004
and 2016. More recently, it was a result of three major pro-
visions of the ACA: the Medicaid expansion, premiums sub-
sidies for those purchasing coverage on the exchanges, and
requiring employers to allow children under the age of 26 to
remain on parents’ family coverage plans.
Perceived access problems have continued to rise in
Switzerland and reached the second highest value (22%)
after the U.S. in 2016. Although Switzerland is the highest
spender on OOP of all ten countries, growth in spending
has been very low (see Fig. 2). The increased barriers there-
fore may have been the result of shifting OOP spending pat-
terns. In fact, people in Switzerland are increasingly opting
for high-deductible plans in exchange for lower premiums,
which may create financial access problems for people with
these plans.
The more striking observation is that Norway shows
low access barriers in spite of OOP spending is the third
highest of the ten countries. The Norwegians seem to
achieve this by having relatively high co-payments
coupled with relatively low ceilings. Low reported access
barriers likely are the result of an equitable spread of
OOP payments among the population. Moreover, the
country enjoys a low unemployment rate and strong so-
cial protection mechanisms.
Discussion
Limitations
Any discussion of OOP spending across countries needs to
be tentative for a variety of reasons, including data availabil-
ity, quality and comparability, different roles of VHI across
countries, and the fact that OOP requirements and
utilization are intertwined such that – and as described
earlier – aggregate trends mask what is occurring at the
individual service level. Nevertheless, cross-country compar-
ability can be enhanced by considering all relevant compo-
nents of OOP spending along the three coverage
dimensions (see Fig. 1), including cost sharing requirements,
voluntary deductibles, direct payments for uncovered ser-
vices, the population covered, and the interaction with VHI
policy. That is the approach that we have taken here.
The data and analyses presented here are subject to sev-
eral limitations. One concerns acquiring and summarizing
data from the ten countries. Aggregate spending data suffer
from frequent breaks in data collection methodology, which
we have tried to control for by taking 10-year intervals. Fre-
quent changes in cost-sharing requirements and in the de-
sign of benefit baskets complicate analyses and comparison
of information across countries. Furthermore, many people
and illnesses are exempt from cost sharing requirements,
so changes reported usually apply only to a subset of the
population.
The data on reported access problems from the Com-
monwealth Fund are also subject to various limitations dis-
cussed earlier. One of the most important is that the
definition of OOP spending may not coincide with the
things a person considers when reporting on cost-related
access problems. For example, both premiums and taxes
pose financial burdens but neither is defined as an OOP
cost. Heightening this problem is the fact that different
countries use these mechanisms to much different degrees.
Second, the data are not broken down by survey respon-
dents’ demographic characteristics. Third, response rates
vary by country, and it is possible that they may be lower
among vulnerable subgroups that may be more likely to ex-
perience access problems. A recent cross-national study by
Cylus and Papanicolas [24] does look at the impact of vari-
ables such as age, education, income, and health status, but
because they use data from a single year (2008), they are
not able to examine changes over time.
Policy implications
The main finding from the first part of the article is that,
while aggregate per capita OOP spending (in PPP per
capita) varies greatly across countries, there is a slow but
steady trend towards convergence. Those countries with
historically low spending levels (France, Netherlands, the U.
K.) have had relatively high growth rates, while the coun-
tries with the highest spending (Switzerland, the U.S.,
Norway) have shown the lowest growth. The four countries
with OOP spending near the middle (Australia, Canada,
Germany, Sweden) also show growth rates in the middle.
This indicates some amount of learning from others’ expe-
riences, but also reflects the possibility that the low spend-
ing countries recognize they have more policy wiggle room
and that the high spending countries recognize they may
have reached the maximum OOP burden of what can be
shifted to consumers.
The key finding from the second part of the article is that
perceptions of the reduced access to care posed by OOP
spending are influenced by three factors: per capita spend-
ing, recent changes in OOP requirements, and the exist-
ence of effective safety mechanisms. It is perhaps not
surprising that the two countries with the highest per capita
OOP spending (Switzerland and the U.S.) show the highest
levels of perceived cost-related access barrier in 2016. Simi-
larly, the country with the lowest aggregate spending level,
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the U.K., has the lowest rate of perceived barriers to access.
But these patterns do not always hold; France also has low
OOP spending, but the third highest rate of perceived cost-
related access barriers in 2016. Conversely, Norway has
high OOP spending, but low perceived cost related access
barriers. This shows that there are more factors driving per-
ceived barriers to accessing care.
Indeed, a second factor driving perceived reductions in
access in some countries is recent changes to cost sharing
requirements. People often evaluate their welfare based
not so much on what they have, but rather, on changes to
the status quo [25]. The Netherlands, a country with his-
torically low OOP spending, provides a case in point. De-
ductibles were introduced in 2008, but they more than
doubled in the two-year period between 2011 and 2013.
Even though the amounts were low compared to countries
like Switzerland and the U.S., this fast rise coincided with
more than one-fifth of the population reporting cost-
related access barriers in 2013 compared to just 6% three
years earlier. As deductibles stabilized, the reported access
problems returned to historic levels (8%) by 2016. Some-
what analogously, France, a country with very low aggre-
gate OOP spending, reports high and growing perceived
access barriers, which are likely due, in part, to increases
in co-payments. Thus, individuals perceive access barriers
based not only how much they have to pay OOP, but also
according to what they are accustomed to paying.
A third factor that appears to affect perceived barriers: the
existence of effective policies to counter high individual
OOP burdens. We distinguish two kinds: safety-net mecha-
nisms and policies aiming to more equally spread the OOP
burden. It is noteworthy that even though Switzerland is,
and has been for some time, an outlier with regard to aggre-
gate OOP spending – with aggregate per capita amounts
60% higher than the U.S. – its population reports far fewer
access barriers. This is due to several factors. First,
Switzerland has achieved universal coverage of its popula-
tion since 1996. Second, children and maternity services are
exempted from most cost sharing requirements. Finally, an-
nual maximums on coinsurance payments exist. In contrast,
the U.S. has far weaker protection mechanisms, with a large
proportion of the population uninsured and very high de-
ductibles in many health plans. Using Norway as an example
to follow, policies could be aimed at more equitably spread-
ing OOP among the population – such as coupling rela-
tively high co-payments with relatively low out-of-pocket
maximums and generous exceptions and protections. The
U.S. movement towards very high deductibles (without pro-
tection mechanisms) has a large impact – both economic
and health – on vulnerable groups.
The two most common complaints about relying on OOP
requirements are related to each other: they provide a bar-
rier to receiving needed care, and they are regressive. Except
for the U.S., where there continues to be a sizable contingent
of uninsured persons, all the countries included in this study
have formulated policies to help shield most of the econom-
ically vulnerable. Those who are protected through lower or
zero OOP requirements include low-income persons (all
countries), children, those with high expenditures, and
people with particular diseases, and older adults. Some of
these mechanisms appear to be more successful than others,
judging from the large amount of variation in perceived
cost-related access problems shown in Fig. 3.
High deductibles are particularly problematic for those
with lower incomes and those who are sicker. Not only are
they regressive by nature, but they can be a formidable bar-
rier to care. If people do not expect to meet their deduct-
ibles during the year, they will behave as though they are
uninsured, and repeatedly studies have shown that such eco-
nomic barriers result in receipt of fewer needed services and
lack of compliance with prescription drug regimens [26].
The two countries that rely most heavily on deductibles –
the U.S. and Switzerland – showed the greatest access bar-
riers in Fig. 3, and as noted the Netherlands also exhibited
such barriers when it substantially increased them.
Of course, other cost containment mechanisms are
available to control costs. “Supply side cost-sharing” pol-
icies such as global budgeting, supply and technology
controls, managed care, and incentive reimbursement of
providers are used in many countries [27, 28], and have
the potential to improve efficiency and equity. Neverthe-
less, as OOP costs are an essential component of finan-
cing sources in all countries, it is important to design
policies that limit as far as possible, their negative conse-
quences for patients.
Conclusions
Since OOP requirements are part of health system
financing in all countries, it behooves policy makers to
find ways to make them less of an access barrier and less
regressive. This requires a better understanding of the
root causes of OOP spending. However, in most coun-
tries OOP data is not gathered in disaggregated fashion,
i.e. broken down into cost sharing and direct payments.
The latter relate to the coverage dimensions of uninsur-
ance (“breadth”) and underinsurance (“scope”, i.e.
lacking benefits) and in many cases these dimensions
may be underestimated. Moreover, more granular data
need to be available to allow for comparisons between
consumer groups (e.g. income-level or health status) to
better understand the differential impacts of OOP
policies and spending across populations. Statistical
agencies should therefore focus their efforts on disaggre-
gating OOP data, so that future research can: (1) better
analyze OOP spending, (2) connect these to actual pol-
icies on the ground, and (3) suggest effective solutions
to policy makers.
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Appendix
Table 3 Key Out-of-Pocket Payment Requirements in the most Recent Year, by Country. This annex contains a table presenting a full
description of all out-of-pocket payment requirements in the ten high-income countries studied in this paper
Depth Scope Breadth
Deductibles Co-insurance and
co-payments
Extra-billing and
reference prices
Protection mechanisms
Australiaa none - specialist ambulatory
care: 15% co-insurance
- prescriptions: co-payment:
AUD38.30
- hospital care: 25%
co-insurance at
private hospitals
- physicians may
bill above fee
schedule
- private hospitals
may bill above
fee schedule
- prescriptions: reduced
co-payment for
low-income and
children: AUD6.20 +
cap at AUD372;
others: cap at
AUD1,476 after
which low-income
co-payment applies.
- ambulatory care:
co-insurance cap AUD447;
cap on OOP for extra
billing at AUD648 for
low income and children
and AUD2,030 for others
(80% of costs are
covered after
reaching the cap)
excluded
services: adult
dental care,
OTC drugs
VHI exists for
excluded s
ervices and
private
hospital care
universal
coverage,
+ VHI held
by about 50%
Canada - for prescriptions
(depending on province)
- prescriptions (depending
on province): co-payment
or co-insurance
- not allowed - prescriptions: provincial
regulations determine
OOP caps and exemptions
- low income: various
provincial programs
cover OOP costs
- tax credits for individuals
whose medical expenses
exceed 3% of
annual income
Excluded
services
(depending on
province):
prescriptions,
vision, dental
care, home
care, rehabilitation,
medical devices/aids
VHI exists for
many of the
excluded services
universal
coverage,
+ two thirds
with VHI
Englandb none - prescriptions:
co-payment GBP8.40
- dental care: GBP19.70,
53.90, or 233.70,
depending on type
of service
- none -exemptions: children, low
income, certain diseases, +
for prescriptions and eye
tests also aged 60+
- annual cap on prescriptions
co-payment (prepayment
certificate): GBP104
Excluded services:
- private services
- vision aids, eye
tests
universal
coverage
France none - physician visits: 30%
co-insurance + €1
co-payment per visit
and lab test/x-ray
- prescriptions: 15–100%
co-insurance + €0.5
co-payment/pack
- inpatient care: co-insurance:
20% + co-payment €18/day
- dental care: co-insurance
(30%) + co-payment €1
- additional co-payment
for expensive care
(>€120): €18
(once per visit or stay)
- 20% of physicians
bill above fee
schedule
- reference prices
exist for dental
care, glasses,
dentures,
hearing aids
(covering as little
as 10% of costs)
- children exempted
from co-payments
- patients with one
of 32 severe chronic
diseases exempted
from co-insurance
- low income (10% of
population) receive free
VHI, free vision care,
free dental care
- complementary VHI
covers co-insurance
- hospital co-payment
limited to 31 days
- €50 caps on co-payments
each for physician visits,
prescriptions, and dental care
none universal
coverage,
+ 95% with
complementary
VHI
Germanyc None - prescriptions and medical
aids: 10% co-insurance
(min €5, max €10)
per prescription
- Hospital co-payment:
€10 per day
- Home nursing,
physiotherapy, etc.:
10% co-insurance + €10
per prescription
- Reference prices
exist for crowns
and dentures
(covering about
50% of normal
treatment),
prescriptions, and
medical aids.
Exemption: Children
under age 18;
Maximum cost-sharing
(does not apply to OOP
above reference prices):
2% of annual income
(1% for patients with
chronic conditions)
excluded services:
OTC drugs,
certain services
of uncertain
benefit or
unfavourable
cost-effectiveness.
universal
coverage;
10% covered
by substitutive
VHI
Netherlands - €385 for all services
except primary care
- 20-25% co-insurance for
non-contracted care
(only for benefits in-kind
insurance policies)
- prescriptions:
OOP above
reference price
deductible exemption:
children < 18, maternal
care, integrated
care programs
excluded services:
adult dental care,
certain prescriptions
(statins, ASS,
universal
coverage
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Table 3 Key Out-of-Pocket Payment Requirements in the most Recent Year, by Country. This annex contains a table presenting a full
description of all out-of-pocket payment requirements in the ten high-income countries studied in this paper (Continued)
Depth Scope Breadth
- medical devices
and aids: OOP
above reference
prices
benzos),
physiotherapy
Norwayd None co-payments:
- primary care:
NOK 152/201
- specialist care:
NOK 345
- physiotherapists:
NOK 98–300
- psychologist:
NOK 345–1035
- dental care for
19–20 years:
25% in co-payment
if services are
provided by
public providers
- prescriptions: 39% of
full price if on
the “blue list”
(max NOK 520/prescription)
- radiology: NOK 245/exam
- lab test: NOK 54
- extra billing of
services/materials
used that are
excluded from
statutory
coverage (this is
not included in
cap 1 or 2) such
as bandage,
consumables
- children under age
16 exempted from
co-payments, up to
18 years for dental care
- Cap 1: max 2205 NOK
during a calendar year
covering primary and
specialist care, radiology
and “blue list” prescriptions
- Cap 2: max 1990 NOK
during a calendar year
covering physiotherapists,
some dental care for
adults (predefined
conditions), some
rehab, and
treatment abroad
when referred by Oslo
university hospital
- tax deductions for
patients with medical
expenses above
NOK 5880
excluded services:
adult dental
care (with some
exceptions for
a few predefined
conditions),
prescription drugs
not covered by
the “blue list”,
services provided
by non-contracted
providers, services
provided or
devices/materials
used that are
excluded from
statutory coverage
(e.g. bandages,
consumables)
universal
coverage
Swedene - prescriptions: 1100 SEK
(for adults> 18)
- dental care: 3000 SEK
(for adults > 22)
co-payments
(varying across the
21 county councils):
- primary care: 120–200 SEK
per physician visit
- specialist care: 200–350 SEK
per physician visit (reduced if
referred from primary care)
- hospitalization: 100 SEK/day
for adults> 19
- medical devices/aids:
co-payment for different
types of devices/aids
co-insurance
(determined at national level):
- prescriptions: 50% between
1100 and 2100 SEK, 25%
between 2100 and 3900
SEK, 10% between 3900 and
5400 SEK (max 2200 in
co-payments for each
12 month period)
- dental care: 50% between
reference prices of 3000 and
15,000 SEK, 15% for reference
prices above 15,000 SEK (applies
for each 12 month period)
- dental care: OOP
above reference
prices
- medical devices/
aids: OOP above
reference prices;
extra billing for
medical devices/
aids not covered in
some county
councils (e.g.
multifocal lenses in
cataract surgery,
advanced hearing
aids)
General exemptions:
- children and young
adults < 22 for dental
care, < 18 for
prescription drugs,
< 20 for
health services
Two separate
co-payment
caps for each
12 month period:
- visits to primary
and outpatient
specialist care
combined: 1100 SEK
- prescription drugs:
2200 SEK
excluded services:
certain medicines,
dental services
and aids with
uncertain benefits
and/or poor
cost-effectiveness;
services provided
by non-contracted
private providers;
vision aids including
eye test
universal
coverage
Switzerland all services: min.
CHF300 – max
CHF2500
- Co-insurance 10% of all
costs above deductible;
- Hospital co-payment:
CHF 15 / day
- medical aids:
patients pay OOP
above reference
price
- Children (< 19 y): no
deductible (or voluntary
between CHF 100
and CHF 600);-
Maximum for
co-insurance:
CHF700/year
(Children: CHF350/year)
- exemptions for
preventive and
maternal care
excluded services:
adult dental
care, OTC drugs,
psychotherapy
performed by
independent
psychologists,
vision aids
Universal
coverage
US Employer plans
- average: US$1318
Medicare:
- hospital care: US$1288
- physician services:
US$166
- drugs: varies by plan
Employer plans:
- average co-insurance:
18–19% primary,
specialist and
hospital care
- average co-payment: US$24
(primary), US$37 (specialist),
US$308 (hospital)
- usually not
allowed
Employer plans:
- median cap on
user charges:
US$3000–3999
Usually excluded:
dental care and
vision care
8.6%
uninsured
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Table 3 Key Out-of-Pocket Payment Requirements in the most Recent Year, by Country. This annex contains a table presenting a full
description of all out-of-pocket payment requirements in the ten high-income countries studied in this paper (Continued)
Depth Scope Breadth
- prescriptions: co-insurance
17–32%, co-payment:
US$11–93
Medicare:
- hospital care: no co-payment
for first 60 days,
US$322/day until day 90
- physician services: 20%
co-insurance
- drugs: varies by plan
aAUD amounts refer to 2016 values; refs: https://www.humanservices.gov.au/customer/enablers/2016-medicare-safety-net-thresholds;
http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee; http://www.commonwealthfund.org/~/media/files/publications/fund-report/2016/jan/
1857_mossialos_intl_profiles_2015_v7.pdf
bValues refer to 2016
cOOP requirements refer to SHI system; requirements for substitute VHI differ
dValues refer to 2015, ref.: http://www.commonwealthfund.org/~/media/files/publications/fund-report/2016/jan/1857_mossialos_intl_profiles_2015_v7.pdf
eValues refer to 2011
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Table 4 Changes in Out-of-Pocket Payment Requirements Over 10-Year Period, by Country. This annex contains a table with a full
description of the changes in out-of-pocket requirements over a 10-year period in the ten high-income countries studied in this paper
Depth Scope Breadth
Deductibles Co-insurance and
co-payments
Extra-billing and
reference prices
Protection
mechanisms
Australia -no change 2005: pharmaceutical
co-payments increased
to AUD28.60
2015, 2016: increase
in pharmaceutical
co-payments
- annual
changes related
to decisions of
physicians
- 2005: incentive payment
to GPs who do not
extra bill
- annual increase in
co-insurance caps
- 2016: introduction of cap
on OOP for extra billing
- minimal
changes
- no change
Canada - no change - provincial level
changes for
prescriptions
- no change - provincial level changes
for low-income and
elderly caps/exemptions
- no federal
level change
but provincial
level changes
- no change
England - no change prescriptions:
- annual increase
of co-payments
by GBP0.10–0.20
dental care:
- 2006: reduction
of co-payments
(maximum reduced
from GBP384 to 189)
- since then regular increase
- no change - regular increase of
prescriptions cap
- no change - no change
France - no change 2005: introduction of
€1 co-payments for
physician visits, lab
tests, x-rays
2006: introduction
of €18 co-payment
for expensive care (>€120)
2008: introduction of
€0.5 co-payment for
prescriptions
2013: increase of daily
co-payment for hospital
care from €16 to €18
- changes related
to choices of
physicians
2005 and 2008:
introduction of €50
caps on co-payments
for each type of service
- minimal
changes
- no change;
continuous
growth of
complementary
VHI coverage
Germany - no change 2013: €10 per physician
visit discontinued
2005: introduction
of reference price
system for crowns
and dentures
- no change - minimal
changes
since 2007:
mandatory
insurance
Netherlands 2008: €150
deductible
introduced
2009–2016:
annual increase
up to €385
since 2010: emergence
of co-insurance for
non-contracted providers
- no change 2014: several
compensations for
chronically ill were
abolished (e.g. partial
compensation for the
mandatory deductible),
but municipalities
may provide such
compensations now.
Many exclusions
and some
inclusions, e.g.:
2006: exclusion
of adult dental care
2007: inclusion of
psychotherapy
(severe cases),
first IVF (of max. 3)
2009: exclusion
of benzos, statins
2009 exclusion
of walkers
2011: exclusion of
dental care for
18–22 y/o
2011/12: reductions
in physical therapy
2012: exclusion of
gastric acid blockers
2013: exclusion of
simple walking aids
2013–14: inclusion
of quit smoking and
- no change
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Table 4 Changes in Out-of-Pocket Payment Requirements Over 10-Year Period, by Country. This annex contains a table with a full
description of the changes in out-of-pocket requirements over a 10-year period in the ten high-income countries studied in this paper
(Continued)
Depth Scope Breadth
Deductibles Co-insurance and
co-payments
Extra-billing and
reference prices
Protection
mechanisms
dietary advice
Norway - no change - small changes to co-
payment amounts, slowly
increasing
- no change - annual revision of
co-payment cap,
slowly increasing
- minimal changes - no change
Sweden - no change - small increases to co-
payment amounts for out-
patient specialist care with-
out referral in several
county councils
- no change 2008: reduced
co-insurance for
dental care above
high cost threshold
2012: OOP caps increase:
- prescriptions: from
SEK 1800 to 2200
- outpatient primary and
specialist care: from SEK
900 to 1100
2016: introduction of
general exemption from
co-payments for
prescription drugs
for children under 18
2009: prescription
drug coverage
restricted to lowest
cost generic
2013: minor
increase in scope of
subsidies in dental
care to elderly
- no change
Switzerland - 2005: max
deductible is
increased
from CHF1500
to CHF2500
- Proportion of
insured opting
for deductible
of CHF2500
increased
from around
5% in 2005 to
19% in 2014
2011: hospital co-payment
is increased from CHF10 to:
CHF 15 / day;
2006: Co-insurance is in-
creased to 20% for brand
drugs if a cheaper generic
is available;
-no change - no change 2011: vision aids
excluded from
coverage;
2012: alternative
and complementary
medicine
included in
benefits catalogue
- no change
US Employer plans:
- average
deductible
increase from
US$602 in
2005 to
US$1318 in
2015
Medicare:
- annual small
increase in
deductibles
Employer plans:
- co-insurance, co-payments
relatively stable
Medicare:
- annual small increase in
co-payments
- no change Employer plans:
- annual 6% increase of
proportion of insured
with cost-sharing cap of
≥US$3000 (33% in
2005, 59%)
- dental care
and vision care
excluded in
increasing
proportion
of plans
- coverage
among the adult
population
increased from
82.9% in 2013 to
89% in 2016 [19]
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